Stay updated on Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.

Latest updates to the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page footer revision marker was updated to **Revision: v3.5.3** (from **v3.5.2**), reflecting an interface/version change rather than any study-record information.SummaryDifference0.0%

- Check10 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check39 days agoChange Detected- Revision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision: v3.4.2 added; prior notice about government funding status (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check83 days agoChange DetectedA site-wide notice about government funding status and NIH Clinical Center operations was added, and the page now shows a revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.